



Massachusetts General Hospital
Corporate & Foundation Relations
Office of Development

PRIVATE FUNDING OPPORTUNITIES: OCT 14, 2016

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

1. Identifying Evidence-Based Solutions for Vulnerable Older Adults, American Association of Retired Persons (AARP) Foundation

AARP Foundation works to ensure that low-income vulnerable older adults have nutritious food, safe, secure and affordable housing, a steady income, and strong and sustaining social bonds. To address those needs, the grant competition is seeking evidence-based solutions that are guided by a deep level of engagement with AARP Foundation and that can be nurtured, evaluated and brought to scale.

Through this grant competition the Foundation hopes to achieve multiple goals:

- Develop a landscape analysis of evidence-based interventions that serve vulnerable older adults and align with our four impact areas
- Create a portfolio of grant-funded programs that includes projects with different levels of evidence with the goal of scaling, at the appropriate time, to serve more low-income older adults
- Identify solutions that seek to achieve a double bottom line (sustainable programs that achieve a positive financial and social return).

Advancing Effective Solutions

As stated in its mission, AARP Foundation is focused on creating and advancing effective solutions around its four impact areas. Below are the objectives for each of the four impact areas for which the Foundation is seeking solutions. The Foundation understands that some interventions may indirectly affect other areas (e.g., increased income security will often result in increased food security) and encourages proposals that have cross-objective impact. However, its wants to make sure the solution does have a primary focus related to at least one of the impact areas that follow. Often by focusing on a single objective, secondary and tertiary results come naturally.

1. Income Security Objectives
2. Food Security Objectives
3. Housing Security Objectives.
4. Social Connectedness Objectives



*Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.*

Innovation Pipeline

To manage its ability to create and advance effective solutions, AARP Foundation has developed an innovation pipeline. Concepts and programs enter the pipeline based upon level of project maturity and evidence. Through this pipeline, programs are piloted, tested and reiterated based on results of the different testing stages. The Foundation does not expect every project will go through each phase of the pipeline (though our goal, in this RFA, is to help each grantee to do so). As a result, it invests smaller amounts of resources in many projects with less evidence and increase the level of investment as the amount of evidence of impact increases.

Award Amount: In general, the following should be considered guidelines, but not strict funding bands:

- Theory of Change/ Pre-Evidence: \$50,000-\$75,000; 9-18 months
- Self-reported Evidence: \$100,000-\$200,000/year; 18-24 months
- Independent Evaluation: \$200,000-\$300,000/year; 24-36 months

Indirect Costs: unpublished

Pre-Application Deadline: Oct 18, 2016

Website: <http://www.aarp.org/aarp-foundation/grants/info-2016/Identifying-Evidence-Based-Solutions.html>

2. Liver Scholar Award, American Liver Foundation (ALF)

The award provides young scientists with support for their research to bridge the gap between completion of research training and attainment of status as an independent research scientist. The additional research experience provided by this award is intended to enable them to successfully compete for research awards from national sources, particularly the NIH. The award is intended to develop the potential of outstanding, young scientists and encourage research in liver physiology and disease. Either basic science or clinical studies are eligible for funding.

While applications on all liver-related research topics will be considered, the following are of particular interest: biliary atresia and primary biliary cirrhosis.

Award Amount: \$225,000 paid over 3 years

Indirect Costs: none

Application Deadline: Dec 2, 2016

Website: http://www.liverfoundation.org/2016_research_awards/liverscholar

3. CURE Epilepsy Award, CURE, Citizens United for Research in Epilepsy

The investigator-initiated grants program seeks to boldly push the envelope and accelerate promising research leading to disease-modifying breakthroughs for people living with epilepsy.

CURE prioritizes highly innovative, often risky, paradigm-shifting projects that address CURE's mission to cure epilepsy, affirming its core belief that the only acceptable final goal is "no seizures, no side-effects."

CURE strongly encourages multidisciplinary, collaborative projects, especially those that are inclusive of investigators and expertise from fields outside of epilepsy.

The following priority areas reflect CURE's focus on scientific advances that have the potential to truly transform and save the lives of those affected by epilepsy. Prevention and disease modification/elimination are critical goals and consistent with its mission:

- Transformative research to enhance our understanding of the cellular, molecular, genetic and systems-level mechanisms that lead to any of the epilepsies, facilitating the continued investigation of disease-modifying or preventative strategies;
- Innovative approaches that can prevent, modify and/or arrest the development of acquired epilepsy after head injury, stroke, tumor, viral infection, etc;
- Research that will inform the development of novel therapies to prevent onset or halt the progression of the severe pediatric epilepsies
- Research focused on new, effective treatments for the >30% of the epilepsy population who are pharmacoresistant;
- Novel research that furthers our understanding of the causes and ultimate elimination of SUDEP.

Award Amount: \$250,000 paid over 2 years

Indirect Costs: none

LOI Deadline: Nov 16, 2016

Website: http://www.cureepilepsy.org/research/grant_cure.asp

4. CURE Innovator Award, CURE, Citizens United for Research in Epilepsy

The award supports the exploration of a highly innovative, often risky new concept or untested theory that addresses an important problem relevant to epilepsy. The proposed research must reflect ideas substantially different from those being pursued by anyone in the epilepsy research field.

The program is not intended to support the logical progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue radically unconventional, paradigm-shifting hypotheses. This award mechanism supports high-risk studies that have the potential to reveal entirely new areas of epilepsy research. Research completed through an Innovator Award must provide sufficient preliminary data to enable the PI to prove or disprove their groundbreaking, original, and/or unconventional hypothesis and have the potential, if the scope of work is successful, to move epilepsy research forward by leaps rather than by incremental steps.

This program awards seed grants to researchers submitting innovative proposals that will provide new directions for epilepsy disease modifying therapies, prevention and, ultimately, a cure. CURE specifically encourages studies that may not be currently fundable by other agencies or other mechanisms because of their preliminary, innovative or unconventional nature.

Award Amount: \$50,000 for 1 year

Indirect Costs: none

LOI Deadline: Nov 16, 2016

Website: http://www.cureepilepsy.org/research/grant_innovator.asp

5. Shark Tank Competition, Epilepsy Foundation

The Epilepsy Therapy Project, an initiative of the Epilepsy Foundation, is inviting entries that represent the most innovative new ideas in epilepsy treatment and care for its sixth annual Shark Tank Competition. The winner(s) will compete for awards to support the development and commercialization of an important new product, technology, or therapeutic concept to help people with epilepsy.

Examples of Novel Concepts

- Drug or device treatment that stops a seizure, especially those already developed or approved for a different indication
- System that helps patients manage their treatment or their epilepsy (less invasive, less costly anti-epileptic drug measurement, for example)
- Device that prevents personal injury from a seizure
- Any other concept that could improve the lives of people with epilepsy potentially in the near future

The proposal must include information about intellectual property, and a brief development outline with milestones for deliverables. The proposal must explain the potential impact on people with epilepsy in terms of the creativity/ingenuity of the concept, as well as significance of this concept as an advancement for people with epilepsy.

Award Amount: \$200,000

Indirect Costs: not published

LOI Deadline: Nov 28, 2016

Website: <http://www.epilepsy.com/accelerating-new-therapies/shark-tank-competition>

6. Career Development Awards in Support of Research Into Inherited Orphan Retinal Degenerative Diseases and Non-Exudative Age-Related Macular Degeneration, Foundation Fighting Blindness (FFB)

The Foundation is soliciting applications from researcher of superior dedication and talent. The award is for junior investigators to pursue vigorous research programs to drive the research to find the therapies and cures for inherited retinal degenerative diseases (RDD). The goal of this program is to facilitate advances in laboratory and clinical research, to elucidate the mechanisms for the etiology and pathogenesis of RDD and to develop innovative strategies to prevent, treat and cure these diseases.

The recipient must be mentored by one or more senior clinician-scientist. Research programs can be clinical or laboratory-based and must address one (or more) of the six designated FFB Priority Research Program Areas that are listed and described below:

Therapeutic Approaches:

- Gene Therapy (GT) - Develop and optimize viral and/or non-viral gene delivery systems for the treatment of dominant, recessive and X-linked retinal degenerative diseases. Demonstrate efficacy and safety using pre-clinical models in preparation for human clinical trials.
- Regenerative Medicine (RM) - Develop strategies to rescue and, ultimately, replace dead retinal cells with cells capable of functional replacement (e.g., stem cells , retinal precursor cells), sufficient to restore lost vision.
- Novel Medical Therapies (NMT) - Develop therapeutic molecules to retain retinal function and structure in retinal degenerative diseases; including the creation of improved animal models of human disease, better functional testing of drug efficacy and novel drug delivery systems.

Basic Research

- Genetics (GE) - Identify disease-causing mutations in inherited retinal disorders, in part by integrating comprehensive genetic testing into routine clinical care. Identify inherited risk factors for age-related macular degeneration (AMD) and the relative contributions of associated genetic and non-genetic factors (e.g., lifestyle), sufficient to incorporate into treatment and preventions.
- Cell and Molecular Mechanisms of Disease (CMM) - Improve the understanding of the nature and cause of disease in inherited retinal degenerations so that improved therapies for the prevention of vision loss can be developed.

Clinical Research

- Clinical: Structure and Function (CL) - Develop improved technology and standardized processes to establish relationships between clinical retina function and retina structure in retinal degenerative diseases and to enable early disease detection.

Awardees may be invited to present a summary of their research at the annual post-ARVO FFB meeting.

Award Amount: \$375,000 paid over 5 years

Indirect Costs: none

Application Deadline: Mar 1, 2017

Website: <http://www.blindness.org/apply-for-funding#cda>

7. Genetics Prize, Peter and Patricia Gruber Foundation

The Foundation rewards excellence globally and encourages achievement on the highest levels in fields that contribute to the well being of our world in both science and human rights.

Nominations for the Genetics Prize are invited annually from the field of genetics. The prize is given in recognition of groundbreaking contributions to any realm of genetics research.

Award Amount: \$500,000 unrestricted

Nomination Deadline: Dec 15, 2016

Website: <http://gruber.yale.edu/genetics-prize-nomination-criteria>

8. Neuroscience Prize, Peter and Patricia Gruber Foundation

This prize honors scientists for major discoveries that have advanced the understanding of the nervous system.

Award Amount: \$500,000 unrestricted

Nomination Deadline: Dec 15, 2016

Website: <http://gruber.yale.edu/neuroscience-prize-nomination-criteria>

9. Independent Grants for Learning & Change (IGL&C): Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Dietary Intakes, Safety, and Public Health Value of Calcium, Pfizer, Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

Geographic Scope: Global

Clinical Area: Bone Health: Calcium & Vitamin D Supplements

Specific Area of Interest for this CGA:

It is Pfizer's intent to support projects that focus on increasing the awareness and understanding of: 1) gaps in dietary intake of calcium (specifically LATAM and APAC); 2) the safety of calcium supplementation with or without vitamin D, with respect to cardiovascular disease; and 3) the public health value of closing dietary gaps in calcium.

Target learner audiences include: 1) healthcare professionals with a focus on prevention and treatment of osteoporosis and 2) General practitioners.

All activity types will be considered through this CGA including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials including published proceedings. An activity taking place alongside the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) is of particular interest.

Award Amount: \$300,000 paid over 2 years

Indirect Costs: unpublished

Application Deadline: Nov 11, 2016

Website: http://www.pfizer.com/responsibility/grants_contributions/grants_process

10. Independent Grants for Learning & Change (IGL&C): Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Role of Key Nutrients and Dietary Supplements for Healthy Skin Appearance, Pfizer, Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

Geographic Scope: United States only

Clinical Area: Dietary Supplements (Skincare)

Specific Area of Interest for this CGA:

It is Pfizer's intent to support projects that focus on increasing the awareness and understanding of the science and the role of key nutrients and dietary supplements for healthy skin appearance.

Areas of special interest include increasing healthcare provider knowledge around assessing dietary supplement benefits for patients and understanding biologic plausibility and effective patient-provider communication.

Target learner audiences include: dermatologists, cosmetic and plastic surgeons and any healthcare professionals involved in the care or treatment of patients with skin aging.

All activity types will be considered through this CGA including live events, satellite symposia, workshops, online courses, print materials, other enduring materials. An activity taking place alongside a dermatology conference, such as the American Academy of Dermatology (AAD) Annual Meeting is of particular interest.

Award Amount: \$250,000

Indirect Costs: unpublished

Application Deadline: Nov 11, 2016

Website: http://www.pfizer.com/responsibility/grants_contributions/grants_process

11. Distinguished Scientist Awards, Sontag Foundation

This award seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.

Applicant's career track and proposed research should demonstrate potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.

Award Amount: \$600,000 paid over 4 years

Indirect Costs: 15%

Application Deadline: Mar 15, 2017

Website: <http://www.sontagfoundation.org/Display.aspx?id=38>